Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study

Journal of Dermatology

Volumn 41, Issue 12, 2014, Pages 1039-1046

  Ohtsuki, Mamitaro ^a   Morita, Akimichi ^b   Abe, Masatoshi ^c   Takahashi, Hidetoshi ^d   Seko, Noriko ^e   Karpov, Alexander ^f   Shima, Tomohiro ^e   Papavassilis, Charis ^f   Nakagawa, Hidemi ^g  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c Sapporo Skin Clinic   (Japan)

^d Takagi Dermatological Clinic   (Japan)

^e NOVARTIS PHARMA K K   (Japan)

^f NOVARTIS PHARMA AG   (Switzerland)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IL 17A; Japan; Psoriasis; Randomized controlled trial; Secukinumab

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; FUMARIC ACID; METHOTREXATE; PLACEBO; SECUKINUMAB; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

5-POINT INVESTIGATOR'S GLOBAL ASSESSMENT SCALE; ADULT; ALOPECIA; AORTA THROMBOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; FEMALE; FURUNCULOSIS; HEART FAILURE; HERPES SIMPLEX; HUMAN; JAPANESE (PEOPLE); LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84915805860     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12668     Document Type: Article

References (17)

1. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
2. Kubota K, Sato T, Ohba N et al., Japanese Society for Pharmacoepidemiology, Nov 16-17 2013, Tokyo. 2013; 39.
3. Takahashi H, Nakamura K, Kaneko F et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011; 38: 1125-1129.
4. Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
5. Pearce DJ, Higgins KB, Stealey KH et al. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat 2006; 17: 288-293.
6. Patel DD, Lee DM, Kolbinger F et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72: ii116-ii123.
7. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014; 141: 133-142.
8. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
9. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimenfinding study. Br J Dermatol 2013; 168: 402-411.
10. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II doseranging study. Br J Dermatol 2013; 168: 412-421.
11. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis: results of two phase three trials. N Engl J Med 2014; 371: 326-338.
12. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003; 14: 158-165.
13. Langley RGB, Feldman SR, Nyirady J et al. The 5-Point investigator's global assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2013. doi: 10.3109/09546634.2013.865009.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
15. Edson-Heredia E, Sterling KL, Alatorre CI et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol 2014; 134: 18-23.
16. Richards HL, Fortune DG, Griffiths CE et al. The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
17. Perrott SB, Murray AH, Lowe J et al. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567-571.